LeMaitre Vascular (NASDAQ:LMAT) Receives “Buy” Rating from Roth Mkm

Roth Mkm reiterated their buy rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report published on Thursday morning,Benzinga reports. Roth Mkm currently has a $117.00 target price on the medical instruments supplier’s stock, up from their prior target price of $108.00.

Several other brokerages have also recently weighed in on LMAT. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Barrington Research reiterated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research report on Friday, February 20th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Finally, Citizens Jmp lifted their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $106.50.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $113.69 on Thursday. The stock’s 50-day moving average is $86.55 and its 200-day moving average is $88.30. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $115.33. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The stock has a market cap of $2.58 billion, a P/E ratio of 45.29, a price-to-earnings-growth ratio of 2.03 and a beta of 0.72.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. The business had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period last year, the company earned $0.49 EPS. The firm’s revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be paid a $0.25 dividend. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.87%.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in LMAT. Vest Financial LLC grew its stake in LeMaitre Vascular by 60.0% in the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock valued at $4,925,000 after acquiring an additional 21,102 shares during the period. SG Americas Securities LLC acquired a new position in shares of LeMaitre Vascular during the third quarter worth approximately $1,101,000. First Trust Advisors LP lifted its holdings in shares of LeMaitre Vascular by 52.7% in the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after purchasing an additional 211,280 shares in the last quarter. Envestnet Asset Management Inc. grew its position in LeMaitre Vascular by 6.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock valued at $25,293,000 after purchasing an additional 19,447 shares during the period. Finally, Congress Asset Management Co. grew its position in LeMaitre Vascular by 2.7% in the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock valued at $60,580,000 after purchasing an additional 18,298 shares during the period. 84.64% of the stock is currently owned by institutional investors.

Key LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and revenue growth — LMAT reported $0.68 EPS vs. $0.67 expected and revenue of $64.45M (vs. $62.98M est.), with revenue up 15.7% year-over-year; this is a primary catalyst for the stock move. Earnings Press Release
• Positive Sentiment: Raised guidance — Management boosted Q1 2026 EPS guidance to $0.640–$0.690 (vs. $0.62 consensus) and FY2026 EPS to $2.810–$3.010 (vs. $2.61 consensus), giving investors clearer upside to future earnings. Guidance Details
• Positive Sentiment: Dividend increase — LMAT declared a quarterly dividend of $0.25 (25% increase from $0.20), raising the yield to ~1.1% and signaling confidence in cash flow; ex-dividend March 12. (Company announcement)
• Positive Sentiment: Analyst bullishness — Roth MKM reaffirmed a “buy” and raised its price target to $117 (from $108), and Citizens JMP raised its target to $118 with a “market outperform” rating; both moves support upside expectations. Benzinga TickerReport
• Neutral Sentiment: Barrington Research raised its price target to $105 and kept an “outperform” rating — a positive signal on the rating but the target is below the current market price, making the impact mixed. Benzinga
• Neutral Sentiment: Relevant reads/transcript — The Q4 2025 earnings call transcript and analyst write-ups are available for investors who want detail on revenue drivers and margin outlook. Earnings Call Transcript
• Negative Sentiment: Wells Fargo raised its target to $94 but maintains an “equal weight” rating — the target sits materially below the current price, which could cap upside or encourage some selling from risk-averse holders. Benzinga

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.